Cambridge, Massachusetts–based Paragonix designed its devices to combine clinically proven, stable, hypothermic preservation technology with an extensive clinical support network. There are digital tools for complete control over the process of organ tracking, monitoring and reporting.
“We are humbled and grateful to be part of transplant patients’ path to a new life while honoring the selfless gift of donor patients with our technology,” Paragonix CEO Dr. Lisa Anderson said in a news release. “Our portfolio of advanced organ preservation and tracking systems provides a safe and effective way for donor organs to be preserved, tracked, and transported to their destination.”
Paragonix has additional positive numbers
The company said that, along with its milestone of 2,000 preserved, transported and tracked donor organs, its research partners have enrolled 1,400 patients in the past three years from 22 transplant centers for the Guardian series of clinical registries.
Additionally, customers have downloaded more than 1,200 data reports on donor organ procurements. The Paragonix app has provided an estimated 800,000d data points related to donor organ transplants, and the company has provided in-person support in more than 800 donor organ procurements.
The company said that, in the second quarter of 2022, its Paragonix SherpaPak CTS helped preserve 27% of all donor hearts transplanted in the U.S.
Combined with the LUNGguard donor long preservation system, the company’s preservation devices played a role in 24% of all U.S. thoracic organ transplants in 2022.
Earlier this year, the company launched the LIVERguard system to offer access to advanced organ preservation to the abdominal market. The system represents an advance in the use of ice and off-the-shelf coolers that have been the standard of care in organ transplantation, Paragonix said. The company also recently announced that it expanded the adoption of LIVERguard to eight U.S. transplant centers.
